仁新(6696)子公司Belite再获国际大型基金1500万美元注资，今日股价跳空开高，一路往上攀升至148.5元，涨幅逼近5%左右。仁新表示，此次增资将充实Belite营运资金，专注LBS-008持续开发，以抢攻全球首款治疗STGD1与GA ...

Belite Bio, Inc ("BLTE" or the "Company") (Nasdaq: BLTE), a clinical-stage biopharmaceutical drug development company focused ...

Belite Bio is a biotech firm specializing in innovative therapies for retinal degenerative eye diseases with high unmet needs ...

Belite Bio (BLTE) announced that it has entered into a securities purchase agreement with a new, fundamental healthcare investor for the ...

分析师修订后的目标价反映了他们预计该药物的平均价格为50,000美元。他们指出，针对罕见遗传性疾病的治疗药物价格可能会显著高于他们的估计。这一更新后的估值并未考虑Tinlarebant在治疗干性年龄相关性黄斑变性（干性AMD）方面的潜力。

Benchmark analysts have increased the price target for Belite Bio, Inc (NASDAQ:BLTE) shares to $79.00, up from the previous target of $57.00, while reiterating a Buy rating on the stock. The decision ...

SAN DIEGO, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc ("BLTE" or the "Company") (Nasdaq: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel ...

Belite Bio, Inc (NASDAQ:BLTE) is possibly approaching a major achievement in its business, so we would like to shine some light on the company. Belite Bio, Inc, a clinical stage biopharmaceutical ...

Belite Bio, Inc. has announced a securities purchase agreement with a new healthcare investor to sell 258,309 American Depositary Shares (ADSs) and warrants at a price of $58.07 per ADS ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...